Effectiveness and Tolerability of Febuxostat vs Allopurinol in patients with Chronic Kidney Disease (CKD) on Conservative Therapy

• Main Authors: Filomena Panza (Author), Chiara Ralli (Author), Ennio Duranti (Author)
• Format: Book
• Published: Archives of Renal Diseases and Management - Peertechz Publications, 2017-06-19.
• Subjects: Research Article
• Online Access: Connect to this object online.

<p>Uric Acid appears to be one of the most important prognostic markers and one of the principal risk factors for cardiovascular diseases. The aim of our study was to assess three groups of patients: a first group treated with Allopurinol (AL), a second group not adequately controlled by treatment with AL or allergic to AL switched to treatment with Febuxostat (AL/FB) and a third group of naive patients immediately treated with Febuxostat (FB). The effectiveness and tolerability of both drugs were therefore assessed over time.</p><p><strong>Materials and methods:</strong> 44 patients, with CKD in conservative therapy, were divided into 3 groups. A group of 20 patients (AL) with well controlled uricemic values (serum uric acid < 6 mg/dl); a group of 12 patients (AL/FB) with not well controlled uricemic values (serum uric acid concentration > 6.0 mg / dl) and / or intolerant to AL that were switched to treatment with FB, then a group of 12 naive patients (FB) treated immediately with FB. At time 0,3,6,9,12,18,24 months, all patients were monitored as regards: serum uric acid, renal function parameters, serum electrolytes, hemoglobin, lipid profile, blood glucose, glycated hemoglobin, proteinuria 24 hours,parathyroid hormone (PTH), C Reactive Protein (CRP). The doses of anti-uric acid administered drug were also evaluated. All the patients underwent a monitoring of blood pressure (BP), heart rate (HR) and body mass index (BMI). </p>